Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Immunotherapy in elderly head and neck cancer patients: a systematic review and meta-analysis

dc.contributor.authorSalvestrini, Viola
dc.contributor.authorCaini, Saverio
dc.contributor.authorScricciolo, Melissa
dc.contributor.authorSaerens, Michael
dc.contributor.authorBollen, Heleen
dc.contributor.authorBonomo, Pierluigi
dc.contributor.authorCaparrotti, Francesca
dc.contributor.authorLorini, Luigi
dc.contributor.authorOliva, Marc
dc.contributor.authorUrbanowicz Nijaki, Maria
dc.contributor.authorSzturz, Petr
dc.date.accessioned2024-07-15T16:08:01Z
dc.date.available2024-07-15T16:08:01Z
dc.date.issued2024-05-10
dc.date.updated2024-06-25T09:59:32Z
dc.description.abstractIntroduction: Over the past years, there has been a growing interest in the role of immunotherapy in locally advanced (LA) and recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). High-quality data from prospective trials are lacking for the elderly subpopulation. This systematic review and meta-analysis aims to review the efficacy and safety of immunotherapy in older patients. Methods: A systematic literature search was conducted. Randomized clinical trials providing outcome data on a subgroup of elderly (>65 years old) were available for meta-analysis. Primary outcomes of interest were OS and PFS for efficacy analysis. Results: Seven studies were included in the systematic review and four in the efficacy analysis. The pooled analysis of OS and PFS showed a consistent benefit (HR 0.78 and 0.91, respectively). Conclusions: Immunotherapy may be an effective and well-tolerated treatment option in the elderly population, but more prospective and randomized data are needed. Systematic Review Registration PROSPERO (CRD42022333891).
dc.format.extent9 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2234-943X
dc.identifier.pmid38800381
dc.identifier.urihttps://hdl.handle.net/2445/214582
dc.language.isoeng
dc.publisherFrontiers Media SA
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3389/fonc.2024.1395838
dc.relation.ispartofFrontiers in Oncology, 2024, vol. 14
dc.relation.urihttps://doi.org/10.3389/fonc.2024.1395838
dc.rightscc by (c) Salvestrini, Viola et al., 2024
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationImmunoteràpia
dc.subject.classificationCura de les persones grans
dc.subject.otherImmunotheraphy
dc.subject.otherElderly care
dc.titleImmunotherapy in elderly head and neck cancer patients: a systematic review and meta-analysis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
fonc-14-1395838.pdf
Mida:
1.85 MB
Format:
Adobe Portable Document Format